Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Organisation › Details

Roche Innovation Center Copenhagen

Santaris Pharma A/S is a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company's research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies address a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with RaNA Therapeutics, Bristol-Myers Squibb, miRagen Therapeutics, Shire plc., Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture and sell products that comprise LNA as active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. *

 

Period Start 2014-08-01 renamed
  Group Roche (Group)
  Predecessor Santaris Pharma A/S
Product Industry LNA™ technology (Locked Nucleic Acid)
Persons Person deBethizy, J. Donald (Santaris Pharma 201401– CEO before Targacept CEO)
  Person 2 Stage, Henrik (Santaris Pharma 201401 CFO)
     
Region Region København (Copenhagen)
  Country Denmark
  City n. a. 
    Address record changed: 2014-08-04
     
Basic data Employees B: 11 to 50 (2005-06-19)
     
    * Document for �About Section�: Santaris Pharma A/S. (10/28/13). "Press Release: Santaris Pharma A/S Resumes Full Ownership of Cancer Programs". Hørsholm & San Diego, CA.
     
   
Record changed: 2017-04-01

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top